![Biotech Stocks Facing FDA Decision In June 2021]( "fda-may24.jpg")
So far this month, only 2 *novel drugs have secured regulatory approval in the U.S. - Johnson & Johnson’s Rybrevant and Apellis Pharmaceuticals’ Empaveli - compared to 6 during the same period last year.
![Biotech Stocks Facing FDA Decision In April 2021]( "fda-march26.jpg")
Four novel drugs were approved by the FDA in March taking the tally of new drug approvals in the first quarter of this year to 14. This compares with 11 new drug approvals in the first quarter of 2020. In all, a total of 53 novel drugs were approved last year.
![Biotech Stocks Facing FDA Decision In January 2021]( "fda2021-dec29.jpg")
As 2020 draws to a close, it’s time to take a look back at some of the regulatory news that made headlines in December and look ahead at what’s in store for January 2021.
![Biotech Stocks Facing FDA Decision In December 2020]( "fda-nov27.jpg")
So far, 46 *novel drugs have secured the official stamp of FDA approval compared to 41 during the same period 2019. *Novel drugs are new molecular entities (NMEs) having chemical structures that have never been approved before.
Let's take a look at the biotech stocks awaiting FDA decision in December.